benralizumab
Selected indexed studies
- Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. (N Engl J Med, 2024) [PMID:38393328]
- Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. (J Allergy Clin Immunol, 2023) [PMID:36538979]
- Benralizumab for the Prevention of COPD Exacerbations. (N Engl J Med, 2019) [PMID:31112385]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. (2023) pubmed
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. (2016) pubmed
- Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. (2020) pubmed
- Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. (2022) pubmed
- Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis. (2022) pubmed
- Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. (2017) pubmed
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. (2016) pubmed
- Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. (2024) pubmed
- Benralizumab for the Prevention of COPD Exacerbations. (2019) pubmed
- Benralizumab: Bringing winds of change to eosinophil-associated diseases. (2025) pubmed